BioLife Solutions (NASDAQ:BLFS) vs. Prestige Consumer Healthcare (NYSE:PBH) Financial Survey

BioLife Solutions (NASDAQ:BLFS) and Prestige Consumer Healthcare (NYSE:PBH) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, risk, earnings, dividends, valuation, profitability and analyst recommendations.

Analyst Recommendations

This is a summary of current ratings and recommmendations for BioLife Solutions and Prestige Consumer Healthcare, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLife Solutions	0	0	7	1	3.13
Prestige Consumer Healthcare	1	3	3	0	2.29

BioLife Solutions presently has a consensus target price of $31.29, suggesting a potential upside of 23.76%. Prestige Consumer Healthcare has a consensus target price of $93.33, suggesting a potential upside of 46.70%. Given Prestige Consumer Healthcare’s higher possible upside, analysts clearly believe Prestige Consumer Healthcare is more favorable than BioLife Solutions.

Earnings & Valuation

This table compares BioLife Solutions and Prestige Consumer Healthcare”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioLife Solutions	$82.25 million	14.72	-$20.18 million	($0.12)	-210.67
Prestige Consumer Healthcare	$1.14 billion	2.75	$214.60 million	$4.26	14.94

Prestige Consumer Healthcare has higher revenue and earnings than BioLife Solutions. BioLife Solutions is trading at a lower price-to-earnings ratio than Prestige Consumer Healthcare, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

93.2% of BioLife Solutions shares are held by institutional investors. Comparatively, 100.0% of Prestige Consumer Healthcare shares are held by institutional investors. 2.2% of BioLife Solutions shares are held by insiders. Comparatively, 1.4% of Prestige Consumer Healthcare shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares BioLife Solutions and Prestige Consumer Healthcare’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioLife Solutions	-5.39%	0.16%	0.14%
Prestige Consumer Healthcare	19.02%	12.69%	6.79%

Volatility and Risk

BioLife Solutions has a beta of 1.78, indicating that its share price is 78% more volatile than the S&P 500. Comparatively, Prestige Consumer Healthcare has a beta of 0.46, indicating that its share price is 54% less volatile than the S&P 500.

Summary

Prestige Consumer Healthcare beats BioLife Solutions on 9 of the 15 factors compared between the two stocks.

About BioLife Solutions

BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.